<DOC>
	<DOCNO>NCT01477632</DOCNO>
	<brief_summary>This trial conduct Europe . The aim trial determine extent bioavailability two low dose estradiol/norethisterone acetate ( NETA ) preparation market estradiol/norethisterone acetate ( NETA ) preparation .</brief_summary>
	<brief_title>Bioavailability Three Oral Formulations Hormone Replacement Therapy Postmenopausal Women</brief_title>
	<detailed_description />
	<mesh_term>Hormones</mesh_term>
	<mesh_term>Estradiol</mesh_term>
	<mesh_term>Polyestradiol phosphate</mesh_term>
	<mesh_term>Norethindrone acetate</mesh_term>
	<mesh_term>Norethindrone</mesh_term>
	<mesh_term>Estradiol 3-benzoate</mesh_term>
	<mesh_term>Estradiol 17 beta-cypionate</mesh_term>
	<mesh_term>Estradiol valerate</mesh_term>
	<criteria>Healthy Postmenopausal Caucasian race Smoking ( 5 cig./per day ) allow Good state health : evidenced medical history , physical examination include gynecological examination , result laboratory examination Known suspect allergy trial product relate product Previous participation trial Previous estrogen and/or progestin hormone replacement therapy Known , suspect history breast cancer Systolic blood pressure ( BP ) least 160 mm Hg and/or diastolic BP least 100 mm Hg , currently treat untreated Body Mass Index ( BMI ) 35.0 kg/m^2</criteria>
	<gender>Female</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>January 2016</verification_date>
</DOC>